TGTX250117C48000
- 0.05
- 0.000.00%
TG Therapeutics Newsroom
TG Therapeutics Reports Strong Revenue and Future Goals
TG Therapeutics Shares Climb 7% as Sales Grow for Multiple Sclerosis Drug
B.Riley Financial Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $38
B.Riley Financial Reaffirms Their Buy Rating on TG Therapeutics (TGTX)
What's Going On With TG Therapeutics Stock Tuesday?
BofA Securities Maintains TG Therapeutics(TGTX.US) With Sell Rating, Maintains Target Price $10
TG Therapeutics Expects Q4 BRIUMVI US Net Product Revenue Of $103.6M, FY24 RIUMVI US Net Product Revenue Of $310M, FY25 Total Revenue Of $540M
Express News | TG Therapeutics Inc Qtrly Briumvi U.S. Net Product Rev Expected to Be $103.6 Mln
TG Therapeutics Sees 2025 Rev $540M >TGTX
Express News | TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones
TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
TG Therapeutics Price Target Raised to $10 From $9 at BofA
BofA Securities Adjusts Price Target on TG Therapeutics to $10 From $9, Maintains Underperform Rating
Express News | TG Therapeutics Inc : BofA Global Research Raises Price Objective to $10 From $9
Jefferies Sticks to Their Buy Rating for TG Therapeutics (TGTX)
Investors in TG Therapeutics (NASDAQ:TGTX) Have Seen Splendid Returns of 185% Over the Past Five Years
Will TG Therapeutics, Inc. (TGTX) Make You Rich In 2025?
Unusual Options Activity: XP, CRS and Others Attract Market Bets, XP V/OI Ratio Reaches 384.6
EST Dec 10th Afternoon Delivery - In the last two hours of trading, 8 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Is TG Therapeutics (NASDAQ:TGTX) Using Too Much Debt?
TG Therapeutics to Participate in the Evercore HealthCONx Conference